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Abstract: Mononuclear phagocytes represent a heterogeneous population of cells with individual subpopula-
tions exerting different pro- or anti-inflammatory functions. CD163 is a monocyte/macrophage specific marker
expressed predominantly on cells which possess strong anti-inflammatory potential. The expression of CD163 is
strongly induced by anti-inflammatory mediators such as glucocorticoids and interleukin-10, while being inhib-
ited by pro-inflammatory mediators such as interferon-gamma. CD163-expressing mononuclear phagocytes, as
well as soluble CD163, may both take part in downregulating an inflammatory response. It seems, therefore,
that CD163 may be an interesting target for therapeutic modulation of the inflammatory response. (Folia His-
tochemica et Cytobiologica 2011, Vol. 49, No. 3, 365–374)
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Introduction
Monocytes and macrophages play an important role
in the regulation of the inflammatory response
[1, 2]. Based on their functional properties, at least two
subpopulations (M1 and M2) of mononuclear ph-
agocytes, which differ in their pro- and anti-inflam-
matory potential, have been described [3]. The cells
of the M1 subpopulation secrete predominantly
pro-inflammatory mediators which trigger and
amplify inflammatory responses. Those of the M2
subpopulation produce mainly anti-inflammatory
mediators which take part in extinguishing inflam-
matory responses, but also play important roles in
wound healing and angiogenesis [1–3]. Several sur-
face molecules have been used to identify those
subpopulations. Recently, CD163 has been pro-
posed to be a specific marker of monocytes/mac-
rophages cell populations exhibiting strong anti-in-
flammatory properties [4]. Although CD163 is
a marker of anti-inflammatory monocytes/macroph-
ages, it also transduces signals upon binding of its
ligands that lead to release of anti-inflammatory
mediators such as interleukin-10 (IL-10).
CD163 is a type I transmembrane protein of 130
kD molecular weight belonging to the group B of the
scavenger receptor cysteine-rich (SRCR) superfami-
ly [4]. Dividing the SRCR superfamily receptors into
two groups, A and B, depends on the number of cys-
teine residues present in each SRCR domain. Those
cysteine residues participate in the formation of dis-
ulfide bonds which affect the folding and stability of
the receptor. Each SRCR domain consists of 100–
–110 amino acids, and makes up part of the extracellu-
lar portion of the scavenger receptors belonging to
that superfamily. Some differences in structure and
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genetics of SRCR domains have been described.
Group A SRCR domains contain six cysteines and
are encoded by two exons, whereas Group B SRCR
domains contain six or eight cysteines encoded by
a single exon [5]. The members of class A and class B
SRCR receptors contain several SRCR domains in
their extracellular regions. Other molecules which
belong to the class B SRCR superfamily, which share
some homology with CD163, include CD5, CD6, Spa,
gp340/SAG/DMBT1, and the most closely related
molecules CD163-L1, WC1 and SCART1.
There are nine SRCR class B domains in the ex-
tracellular part of CD163 (Figure 1). The sixth and
seventh SRCR domains are separated by a short pro-
line-serine-threonine rich interdomain segment en-
coded by a separate exon. The receptor also contains
a transmembrane part spanning the plasma mem-
brane once, and a short intracellular tail which con-
tains consensus sequences for phosphorylation with
protein kinase C and creatine kinase [4]. CD163 is
heavily glycosylated with N-linked glycans. Treatment
of CD163 with endoglycosidase F significantly reduces
the molecular weight of CD163 [6].
Moreover, CD163 also exists as a soluble protein
(sCD163) [4]. It is detectable in the plasma of healthy
persons and can also be detected in body fluids such
as synovial fluids [4]. It contains most of the extracel-
lular part of the membrane CD163, including all
SRCR domains [4].
Gene structure
The CD163 gene is located on the short arm of chro-
mosome 12 (p13.31) [7]. A gene encoding CD163
molecule-like 1 is also located in the same region close
to CD163. The CD163 molecule-like 1 (CD163-L1)
gene is highly homologous to the CD163 gene and
has the same orientation, suggesting that both genes
might originate from a duplication of a single ances-
tor gene. Other genes located in close proximity to
CD163 include: complement component 1s and 1r,
tumor necrosis factor receptor-1, lymphotoxin-beta
receptor, alpha2-macroglobulin, CD9, CD27, and
CD69 [7]. The CD163 gene spans more than 35 kb
and consists of 17 exons and 16 introns [7, 8] (Figure 1).
The first ATG codon is located in exon 1, and that
exon also contains the N-terminal part of the signal
peptide. The remaining parts of the signal peptide
are encoded by exon 2 and the first two nucleotides
of exon 3. Exons 3 through 8 and exons 10 through 12
encode nine SRCR domains. Each exon encodes
a separate SRCR domain. Exon 9 contains 93 bp and
encodes a short proline-serine-threonine rich inter-
domain segment of the receptor, which separates the
sixth from the seventh SRCR domains. The 24 amino
acid transmembrane part is encoded by a 72 bp re-
gion within the exon 14. That exon also encodes the
C-terminal end of the extracellular part and the
N-terminal end of the intracellular part of CD163.
The stop codon is located within exon 16, and exons
15 and 16 encode the C-terminal part of the intracel-
lular tail. The 3’ untranslated region (3’UTR) is en-
coded by part of exon 16 and by exon 17 [7, 8].
The promoter region of human CD163 lacks the
canonical TATA consensus sequence, which is a feature
of genes specifically expressed by myeloid cells [8, 9].
Consistent with the absence of TATA-box, several tran-
scription start sites have been described, with the major
transcriptional start site being located 101 bp upstream
from the first ATG codon. In the promoter region, bind-
ing sites for transcription factors important for myeloid
gene expression have been identified. Those include
transcription factors of Ets-family (Ets and PU.1),
Zn-finger family (Sp1), AP-1 family (AP-1) and C/EBP
family (C/EBPa). Moreover, several putative binding
sites for the glucocorticoid receptor and STAT-family
transcription factors have also been demonstrated in the
promoter region of the CD163 gene [8, 9].
Figure 1. Schematic representation of genomic organization of CD163 gene in relation to individual structural parts of
CD163 molecule
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Several alternative splicing variants of CD163
mRNA have been described. These include different
splice variants in the 5’ as well as in the 3’ ends of the
mRNA, and some of them may encode truncated
CD163 protein [7, 8]. No functional role for these
individual CD163 splice variants has yet been de-
scribed [7, 8].
Murine CD163 is highly homologous to human
CD163 [10]. The gene encoding mouse CD163 is lo-
cated on chromosome 6 in close proximity to com-
plement components 1r and 1s and to CD9 [11]. That
location is homologous to the gene cluster on human
chromosome 12p13.3, which contains the human
CD163 gene. Like human CD163, mouse CD163 is
a type I transmembrane protein which contains
a short (38-amino acid) signal peptide, nine SRCR
domains, one transmembrane domain and a short
cytoplasmic tail [10, 11]. High degrees of homology
are also seen among swine, rat, monkey and human
CD163 receptors [4].
Expression of CD163 protein
CD163 gene expression is tightly regulated in both
a tissue-specific and a differentiation-specific manner
[8, 12]. It is detectable as both a cell surface receptor
and also as a soluble form [13]. Cellular expression
of CD163 is restricted to monocytes and macrophag-
es [8, 12]. Freshly isolated peripheral blood mono-
cytes express a relatively low level of CD163, but this
expression increases with differentiation of such cells
into macrophages [14–17]. Original reports using
Ber-Mac3 or RM3/1 antibodies demonstrated expres-
sion of CD163 on 5% or 30% of freshly isolated mono-
cytes, respectively [14, 15]. More recent reports, how-
ever, have demonstrated CD163 expression on a ma-
jority of peripheral blood monocytes [16, 17]. The
discrepancies in reported expression of CD163 on
freshly isolated peripheral blood monocytes may be
explained by the application of different antibodies
and by different techniques used for monocyte isola-
tion. Even the use of different anticoagulants in the
cell selection process may result in differing intensity
of CD163 staining [17]. Moreover, circulating mono-
cytes represent heterogeneous cell populations with
different expressions of CD163 on individual cell sub-
populations. When monocytes are divided according
to their expression of the endotoxin receptor (CD14)
and the high affinity immunoglobulin G receptor type
III (FcgRIII — CD16), four different subpopulations
can be distinguished [18, 19]. The highest expression
of CD163 is found on CD14highCD16+ and the lowest
on CD14lowCD16– cells [18, 19]. Cells in the
CD14highCD16+ subpopulation have been reported to
exert predominantly anti-inflammatory functions.
Most tissue macrophages, with the exception of lym-
phoid follicle macrophages, express CD163 on their
surfaces and the expression is particularly high on liver
Kupffer cells and on peritoneal and alveolar macroph-
ages [12, 20]. The level of expression of CD163 on
tissue macrophages has been shown to increase dur-
ing the resolution of acute inflammatory response or
during the wound healing phase [21, 22]. Neither gran-
ulocytes nor dendritic cells express significant levels
of CD163. Expression of CD163 also depends on the
maturation stage of monocytes/macrophages. To date,
only one monocytic cell line, SU-DHL-1, has been
shown to express CD163 [18]. Other mouse or hu-
man monocytic cell lines, including THP-1, U937,
HL-60, P338, MonoMac6, RAW264.7 and J-774A.1,
express no detectable CD163 at the mRNA level, ei-
ther spontaneously or upon stimulation with phorbol
esters (PMA) [18]. Glucocorticoid treatment, how-
ever, can induce CD163 expression on some of these
cell lines, e.g. HL-60 [18]. Many pro- and anti-inflam-
matory mediators strongly affect CD163 expression
(Table 1) [14–16, 18, 20, 22–33]. Expression of CD163
is strongly up-regulated by anti-inflammatory media-
tors including glucocorticoids and interleukin-10
(IL-10) [16, 18, 23–26]. In fact, in experiments utilizing
gene-chip technology, CD163 displays the strongest
response to IL-10 among all 19 of the up-regulated
genes [25]. Interleukin 10 is also responsible for up-
-regulation of monocyte/macrophage CD163 expres-
sion induced by CD4+CD25+Foxp3+ T regulatory cells
and for rebound up-regulation of monocyte/macroph-
age CD163 expression after shedding of the receptor
in response to Toll like receptor (TLR) stimulation
[27, 28]. Glucocorticoids are at least equally potent
inducers of CD163 expression [16, 26]. The magni-
tude of up-regulation of CD163 expression depends
on the potency of the glucocorticoid: those having the
greatest affinity for the glucocorticoid receptor are
the most potent for up-regulating CD163 expression
[26]. Concomitant application to macrophages cul-
tured in vitro of dexamethasone and IL-10 exerts an
additive effect on CD163 expression [16]. Endoge-
nous pro-inflammatory cytokines such as tumor ne-
crosis factor-alpha (TNF-a), IL-1a, IL-1b or chemok-
ines such as CXCL-8 (IL-8) decrease expression of
CD163 [16]. Similarly, exogenous pro-inflammatory
molecules such as lipopolysaccharide (LPS) also de-
crease expression of CD163 [28, 29]. Interestingly, not
only a Th-1 type cytokine (interferon-gamma; IFN-g)
but also Th-2 type cytokines (IL-4 and IL-13) down-
-regulate CD163 expression [16]. These cytokines can
suppress not only up-regulation of CD163 expression
associated with differentiation of monocytes to mac-
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rophages, but also dampen IL-10- or glucocorticoid-
-induced CD163 expression [16]. Surprisingly, trans-
forming growth factor-beta (TGF-b), which is an anti-
-inflammatory mediator, inhibits CD163 expression
[30]. Growth factors which induce differentiation of
monocytes into macrophages, such as macrophage
colony stimulating factor (M-CSF), enhance CD163
expression, while those inducing differentiation of
monocytes to dendritic cells, such as granulocyte
macrophage colony stimulating factor (GM-CSF),
down-regulate expression of CD163. Interleukin-6,
which exerts pro- and anti-inflammatory effects on
mononuclear phagocytes, enhances expression of
CD163 [18].
Several chemokines have also been reported to
affect CD163 expression on mononuclear phago-
cytes [16, 31]. CCL-3 (MIP-1a) and CXCL-8 down-
-regulate spontaneous and glucocorticoid-induced
CD163 expression on cultured human monocytes
[16]. Monocytes cultured in vitro in the presence
of CXCL-4 express less CD163 than those cultured
without that chemokine. Moreover, CXCL-4 pre-
vented up-regulation of CD163 expression by
M-CSF [31].
Activation of cell membrane Toll-like receptors
(TLRs), such as TLR-2, TLR-4 or TLR-5, leads to
a rapid down-regulation of CD163 expression by
monocytes/macrophage cells [28]. This down-regu-
lation of CD163 expression is caused by shedding of
CD163 from the cell surface, which has been shown
to involve a metalloproteinase-dependent process
[29, 32]. The same mechanism is responsible for
down-regulation of monocyte CD163 expression by
oxidative stress or 8-iso-prostaglandin F2a [33]. Pro-
longed stimulation with cell membrane TLR ago-
nists, however, leads to a rebound up-regulation of
CD163 to levels higher than those observed before
stimulation with TLR ligands [28]. This effect de-
pends on delayed release of IL-6 and IL-10 by mono-
nuclear phagocytes in response to TLR activation.
When IL-6 and IL-10 are blocked, no rebound up-
-regulation of CD163 expression is seen [28]. Clas-
sical activation of monocytes/macrophages with IFN-g
prevents up-regulation of CD163 in response to pro-
longed activation with TLR agonists [28]. Activation
of intracellular TLRs does not, however, affect
CD163 expression. Other factors which down-regu-
late CD163 expression include hypoxia and cross-
linking of Fcgamma receptor (FcgR) [34, 35]. Hy-
poxia leads to inhibition of CD163 at the transcrip-
tional level, while cross-linking of FcgR results in
shedding of CD163 from the cell surface [34, 35].
Immunoglobulin G immobilized on a culture plate,
or complexes of IgG with an antigen, induce CD163
Table 1. Factors involved in regulation of CD163 expression
Factors up-regulating expression of CD163 Factors down-regulating expression
on monocytes/macrophages of CD163 on monocytes/macrophages
Glucocorticoids Tumor necrosis factor-alpha (TNF-a)
Interleukin-10 Interleukin-1 alpha (IL-1a)
Interleukin-6 Interleukin-1 beta (IL-1b)
Macrophage colony stimulating factor (M-CSF) Interleukin-4
Interleukin-13
CCL-3 (MIP-1a)
CXCL-4
CXCL-8 (IL-8)
Interferon-gamma (IFN-g)
Transforming growth factor-beta (TGF-b)
Granulocyte macrophage colony stimulating factor (GM-CSF)
Lipopolysaccharide (LPS)
Stimulation of Toll-like receptors TLR-2, TLR-4, TLR-5*
Oxidative stress
Hypoxia
Cross-linking of Fcgamma receptor (FcgR)
8-iso-prostaglandin F2a
*Prolonged stimulation with TLR agonists, however, leads to a rebound up-regulation of CD163 to levels higher than those observed before
stimulation with TLR ligands through induction of IL-10 and Il-6
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shedding. This phenomenon depends on the pres-
ence of native IgG, since denaturing of IgG totally
aborts the shedding [35]. Interestingly, in contrast
to prolonged TLR stimulation which results in
IL-10-dependent up-regulation of CD163 expres-
sion, long-term stimulation of FcgR does not cause
rebound up-regulation of CD163 expression on
mononuclear phagocytes [35].
CD163 also exists as a soluble protein (sCD163)
detectable in the plasma of healthy humans [13]. The
median serum concentration seen in healthy subjects
is approximately 1.9 mg/L [13]. Plasma concentrations
vary, particularly in patients with inflammatory dis-
eases such as rheumatoid arthritis, asthma, multiple
sclerosis, or celiac disease [36–39]. Elevated plasma/
/serum concentrations of sCD163 have also been re-
ported in infectious diseases such as pneumonia, sep-
sis, meningitis or tuberculosis, in myeloid leukaemias,
in atherosclerosis and in Gaucher disease which is
characterized by the accumulation of tissue macroph-
ages [13, 40–44]. Moreover, detectable levels of
sCD163 in body fluids such as the synovial fluid of
patients with rheumatoid arthritis or with spondyloar-
thropathy have been reported [36, 45]. The main
mechanism responsible for the appearance of sCD163
in body fluids is thought to be shedding of CD163
from the cell surface of mononuclear phagocytes
[29, 32]. At least two enzymes have been implicated in
this process: matrix metalloproteinase-9 (MMP-9) [29]
and tumor necrosis factor alpha-converting enzyme
(TACE/ADAM17) [32]. An association between plas-
ma MMP-9 levels and plasma sCD163 concentrations
has been demonstrated in multiple sclerosis patients,
supporting a role of MMP-9 in the regulation of
CD163 shedding in vivo [38]. Several alternative splice
variants of CD163 mRNA, which code for truncated
forms of CD163 protein, have been reported. The
transcriptional and/or translational regulation of
CD163 expression does not seem to be the main mech-
anism affecting sCD163 levels.
Intravenous administration of hydrocortisone to
healthy volunteers resulted in enhanced CD163
mRNA and protein expression on peripheral blood
monocytes [46, 47]. Elevated numbers of CD163+
monocytes have been seen as soon as six hours after
intravenous administration of glucocorticoids, and
lasted for at least four days [46]. The maximum effect
was seen between 12 and 24 hours after administra-
tion of glucocorticoids when more than 80% of mono-
cytes stain positive with anti-CD163 antibody [46].
Applying different doses of a glucocorticoid has dem-
onstrated that the peak effect is much less dose-de-
pendent than are the rapidity and duration of the re-
sponse [46].
Function in inflammation
Since its first description in 1987, CD163 (RM3/1)
has been associated with the down-regulatory phase
of the inflammatory process [22]. However, until 2001,
an understanding of the biological role of CD163 was
hampered by the fact that no naturally occurring
ligand of CD163 was known and, therefore, the mech-
anisms of its anti-inflammatory action remained elu-
sive [4]. The application of monoclonal antibodies that
cross-link CD163, such as RM3/1, causes cell activa-
tion and the subsequent release of pro-inflammatory
cytokines, including IL-6 and GM-CSF [48]. This ef-
fect, however, does not seem to be responsible for
the main anti-inflammatory effects of CD163. One
of the anti-CD163 antibodies, Ki-m8, possesses ago-
nistic properties, and it has been shown that applica-
tion of this antibody leads to induction of IL-10 se-
cretion by mononuclear phagocytes [49].
In 2001, Kristiansen et al. demonstrated that
CD163 binds to hemoglobin-haptoglobin (Hb-Hp)
complexes, resulting in internalization of the complex-
es and preventing oxidative stress and inflammation
associated with extracellular metabolism of Hb [50].
Using a ligand-affinity approach, CD163 was shown
to be a specific receptor for Hb-Hp complexes, but
not for Hb or Hp alone [50]. When released from
erythrocytes, Hb binds to Hp to form complexes con-
taining at least two Hb molecules. Formation of these
complexes results in exposure of a new epitope, which
allows binding to CD163 [50, 51]. The binding site
for Hb-Hp complexes is located within the 3 SRCR
domain, and the binding process is both a calcium-
and pH-dependent phenomenon [50, 51]. When cal-
cium concentration is below 0.5 mM, or pH is below
6.5, rapid dissociation of Hb-Hp from CD163 occurs
[50, 51]. Binding of Hb-Hp to CD163 activates the
intracellular signaling which triggers release of IL-10
[49]. Subsequently the Hb-Hp-CD163 complex is in-
ternalized and Hb-Hp is delivered to early endosomes,
where CD163 dissociates and recycles to the plasma
membrane, while Hb-Hp undergoes intracellular
metabolism within the lysosomes [52]. The heme un-
dergoes intracellular degradation by the rate-limit-
ing enzyme heme oxygenase-1 (HO-1), giving rise to
free iron, biliverdine and carbon oxide (CO) [49, 53].
Altogether, the interaction of Hb-Hp with CD163
leads to release of IL-10 and CO, which exert strong
anti-inflammatory effects. The release of IL-10 and
CO by macrophages in response to binding of Hb-
-Hp complexes has been demonstrated in vitro and in
vivo [49]. Moreover, IL-10 acting in an autocrine and/
/or paracrine manner further up-regulates CD163 and
HO-1 expression, creating a positive feed-back loop
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involved in efficient clearance of Hb and protection
against triggering of an inflammatory response by
extracellular Hb. Therefore, protection against Hb-
-induced inflammatory response conferred by CD163
is associated not only with scavenging of Hb-Hp com-
plexes from the extracellular milieu but also with ac-
tive release of anti-inflammatory mediators such as
IL-10 or CO (Figure 2).
Recently several other ligands of CD163, which
play a role in the inflammatory response, have been
described [54–58]. Screening of a combinatorial pep-
tide library designed to search for a tumor necrosis
factor-like weak inducer of apoptosis (TWEAK,
TNFS12) ligands led to the discovery of motifs sim-
ilar to those present in CD163 [54]. The discovery
was reinforced by direct protein-protein interaction
experiments, which showed that TWEAK specifically
binds to CD163 [54]. TWEAK is a member of the
TNF superfamily and plays many important roles in
the processes associated with tissue damage and re-
pair, e.g. inflammation, proliferation, apoptosis and
angiogenesis [59]. Its ability to regulate innate and
adaptive immune response seems to be one of the
most interesting aspects of TWEAK from an immu-
nological point of view [60]. In mice with genetically
silenced TWEAK (TWEAK –/–), systemic adminis-
tration of LPS results in a stronger inflammatory re-
sponse with greater production of IFN-g and IL-12,
but with less IL-10 than in wild-type mice [60]. This
is associated with the development of more robust
Th-1 type immune response [60]. In fact, TWEAK–/
/– mice are more resistant to the development of neo-
plasms whose growth is controlled by a Th-1 type
immune response [60]. Similarly, neutralization of
TWEAK by monoclonal antibodies resulted in aug-
mented production of IFN-g and IL-12 by human
peripheral blood mononuclear cells cultured in the
presence of LPS [60]. The major TWEAK receptor,
fibroblast growth factor-inducible 14 (Fn14), is re-
sponsible for the signal transduction and cellular ef-
fects of TWEAK [59]. Many cells, including fibro-
blasts, endothelial cells and epithelial cells, release
a broad range of chemokines, pro-inflammatory cy-
tokines and matrix metalloproteinases (MMPs) in
response to stimulation by TWEAK [57]. Monocytes
express little or no Fn14 [54, 59]. They do, however,
bind specifically TWEAK, and CD163 is responsi-
ble for that binding [54]. Further experiments re-
vealed that the TWEAK binding site on CD163 is
located in the region responsible for binding of Hb-
-Hp complexes [54]. Analysis of protein databases
showed that TWEAK contains regions with high
homology to Hb and Hp beta chains, which may ex-
plain some similarities of the interactions of those
proteins to CD163 [54]. Functional studies have
demonstrated that the interaction of TWEAK with
CD163 leads to neutralization of both molecules,
suggesting that CD163 may function as a ‘decoy’ re-
Figure 2. Schematic representation of anti-inflammatory effects mediated by CD163
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ceptor for TWEAK [54]. In fact, CD163 inhibits the
apoptotic activity of TWEAK. On the other hand,
in the presence of TWEAK, activation of monocytes
by an anti-CD163 GHI/61 antibody is attenuated,
indicating the presence of a common binding site
on the CD163 molecule [54]. Indeed, high concen-
trations of sCD163 in plasma may be at least par-
tially responsible for the lack of acute phase inflam-
matory response following systemic administration
of TWEAK in mice [60]. Interestingly, IFN-g differ-
entially regulates TWEAK and CD163 expression,
inducing expression of the former and inhibiting
expression of the latter [18, 59]. Moreover, TWEAK
impairs transition from innate to adaptive immuni-
ty which is associated with inhibition of IL-12 and
IFN-g production [60]. Inhibition of TWEAK by
CD163 may, therefore, skew the inflammatory re-
sponse towards a Th-1 type immune response. On
the other hand, TWEAK induces synthesis of many
other pro-inflammatory mediators such as GM-CSF,
IL-8 and RANTES, so inhibition of TWEAK by
CD163 may in this way participate in extinguishing
inflammation [59]. This may explain how during the
inflammatory response, expression and function of
those molecules may be tightly coordinated by pro-
and anti-inflammatory cytokines.
CD163 binds not only to endogenous but also
to exogenous ligands such as bacteria and viruses
[56–58]. Gram-positive and gram-negative bacte-
ria have each been shown to bind CD163 [56].
CD163 expressed on cell membrane as well as an
immobilized protein efficiently binds bacteria.
A peptide motif, GRIEIKFQGRW, located within the
second SRCR domain of CD163, has been shown
to be the major binding site [56]. Some binding
ability by a peptide motif, GRLEVRFQGEW, in
the third SRCR domain has also been demonstrat-
ed [56]. The binding by the latter motif was, how-
ever, consistently less efficient than that by the
former one [56]. Interestingly, recognition of bac-
teria by CD163 results in amplification of pro-in-
flammatory cytokine production, including TNF-a,
IL-1b and IL-6, by mononuclear phagocytes, a re-
sponse similar to that seen during TLR activation
[56]. However, CD163, in contrast to TLRs, can
recognize and bind intact bacteria and not only sol-
uble microbial components [56].
In pigs, an important role of CD163 in viral infec-
tions has been demonstrated [57, 58]. Two viruses,
African swine fever virus (ASFV) and porcine repro-
ductive and respiratory syndrome virus (PRRSV), use
CD163 as an entry into the target cells of pigs
[57, 58]. The ASFV uses CD163 as a binding and in-
ternalization receptor, while for PPRSV, CD163 also
plays a role in the uncoating process [57, 58]. The
susceptibility to infection for both viruses is propor-
tional to the expression of CD163 on the cell surface
[57, 58], and the viruses have a very restricted cell
tropism for the monocyte/macrophage cells [57, 58, 61].
In a study of swine bone marrow monocyte precur-
sors, peripheral blood monocytes and alveolar mac-
rophages, the susceptibility of infection by ASFV was
dependent on the degree of maturation of mononu-
clear phagocytes, being the lowest in bone marrow
cells and the greatest in alveolar macrophages [57].
This was associated with differences in expression of
CD163 on those various cells, being most abundantly
expressed on alveolar macrophages [57]. Moreover,
in vitro maturation of peripheral blood monocytes,
which is associated with up-regulation of CD163, led
to increased susceptibility of those in vitro matured
cells to ASFV infection [57]. Although the natural
host for the PPRSV is the pig, expression of dog,
mouse, monkey or human CD163 can render cells at
least partially permissive for PPRSV infection and
replication [58, 61]. A series of mutation and genetic
recombination studies have demonstrated that the
fifth, but not the first, second or ninth, SRCR domain
of CD163 is crucial for binding and internalization of
PPRSV [62].
Altogether, studies strongly support the notion
that membrane-bound CD163 functions as a recep-
tor for endogenous and exogenous ligands, thereby
participating in the initiation and/or perpetuation of
the inflammatory response. Interestingly, the inter-
action of CD163 with some of its ligands results in
a strong anti-inflammatory response, while other
ligands trigger release of pro-inflammatory mediators.
The particular response may at least partially depend
on the location of the ligand binding site within the
extracellular portion of CD163.
Not only does cell surface CD163 play a role in
the modulation of the inflammatory response, solu-
ble CD163 (sCD163) also can actively regulate that
process. Soluble CD163 inhibits T cell proliferation
[63, 64]. Purified sCD163 inhibited in a dose-depen-
dent manner phorbol ester-induced T cell prolifera-
tion in vitro, at an optimal concentration of sCD163
of 0.5 mcg/ml [63, 64]. This anti-proliferatory func-
tion of CD163 seems to be restricted to its soluble
form, as membrane-bound CD163 does not exert such
an effect [64]. The interaction between sCD163 and
T lymphocytes is mediated by binding of sCD163 to
non-muscle myosin heavy chain in T lymphocytes [65].
The associations between T cell proliferation and
CD163 also come from in vivo studies in which ele-
vated tissue expression of sCD163 is found in places
where T cell proliferation is attenuated [66]. In par-
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ticular, in patients with rheumatoid arthritis, histo-
logical analysis of the inflamed joints revealed that
wherever intense T cell proliferation was observed,
little or no CD163 was seen on tissue macrophages
[66]. Similarly, in asthmatic patients who develop pro-
longed airway inflammation associated with activa-
tion of allergen specific T cells, decreased expression
of monocyte CD163 and lack of increase in plasma
sCD163 concentrations were demonstrated. On the
contrary, asthmatic patients who did not develop late
asthmatic response after allergen challenge were char-
acterized by elevated concentrations of plasma
sCD163 and an increase in monocyte CD163 expres-
sion [37]. Resolution of inflammatory response after
allergen exposure is, therefore, associated with high
plasma sCD163 concentrations, which is in line with
original descriptions of elevated CD163 expression
during resolution of inflammation. These findings may
indicate that in allergic asthmatics CD163 is involved
in the regulation of inflammatory response to aller-
gen challenge. In chronic obstructive pulmonary dis-
ease (COPD), substantial expression of CD163 has
been demonstrated on macrophages derived from
bronchoalveolar lavage (BAL) or induced sputum
[67]. Smoking cessation leads polarization of mac-
rophages towards an anti-inflammatory phenotype,
which is reflected by a higher percentage of macroph-
ages expressing CD163 in BAL derived from ex-smok-
ers. This study clearly demonstrates that exposure to
tobacco smoke, an exogenous pro-inflammatory fac-
tor, is associated with downregulation of CD163 on
BAL macrophages skewing the balance towards on-
going inflammatory response.
A recent study by Higashi-Kuwata et al. revealed
increased expression of CD163 on skin macrophages
and peripheral blood monocytes from patients with
systemic sclerosis (scleroderma), an autoimmune dis-
ease characterized by local inflammatory infiltrates
and widespread fibrosis [68]. The role of increased
CD 163 in the pathogenesis of systemic sclerosis re-
mains to be established.
Perspectives
Evaluation of CD163 expression would appear to be
an interesting avenue in the assessment of the anti-
-inflammatory function(s) of monocytes/macrophag-
es. CD163 is expressed primarily by monocytes/mac-
rophages; therefore, it might be regarded as a rela-
tively specific marker of monocyte/macrophage func-
tion. Moreover, variable degrees of up-regulation of
CD163 expression by glucocorticoids may explain, in
part, the anti-inflammatory effects of different glu-
cocorticoids in vivo. It seems likely that evaluation of
CD163 expression in tissues or body fluids may also
be a useful marker of local anti-inflammatory effects
of glucocorticoids. Further studies are needed to con-
firm such an approach. The CD163 molecule might
also prove to be an interesting therapeutic target. It
is strongly up-regulated by anti-inflammatory media-
tors, e.g. glucocorticoids and IL-10, and both mem-
brane-bound and soluble CD163 may at least partial-
ly mediate the anti-inflammatory effects of glucocor-
ticoids. Therefore, one might speculate that applica-
tion of sCD163 might be used for modulation of
inflammatory responses in different clinical settings.
A potential advantage of CD163 over glucocorticoids
is that modulating CD163 might be devoid of the
metabolic effects that are common adverse effects
associated with the use of glucocorticoids in treating
various immune diseases. Moreover, CD163 is a mol-
ecule naturally occurring in the human organism and,
therefore, application of that molecule should not be
associated with induction of an immune response such
as allergic response.
Summary
CD163 plays a role in the regulation of the immune
response. It affects the innate immune response as well
as modulating the development of the adaptive immune
response. Assessment of CD163 expression in differ-
ent diseases may prove to be useful for the evaluation
of disease severity and prognosis. Moreover, it may help
in evaluation of anti-inflammatory therapy such as glu-
cocorticoid therapy. Finally, targeting CD163 may be
an interesting therapeutic approach for the treatment
of many inflammatory diseases.
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